Background Even though the lives of millions have been saved in the past decades, the
mortality rate in patients with drug-resistant tuberculosis is still high. Different factors are …

Introduction: Drug-resistant tuberculous meningitis has been reported worldwide. Isoniazid
mono-resistance is the most frequent cause of drug-resistant tuberculous meningitis, a life …

Drug-resistant tuberculosis (DR-TB) remains a major global health problem. Early treatment
of TB is critical; in the absence of rapid-susceptibility testing, the empiric selection of drugs …

The burden of multidrug-resistant tuberculosis (MDR-TB) related to mortality in resource-
poor countries remains high. This study aimed to estimate the incidence and predictors of …

Fluoroquinolones are group A drugs in tuberculosis guidelines. We aim to compare the
culture conversion between new-generation (levofloxacin and moxifloxacin) and old …

The aim of this study was to evaluate long-term survival and risk factors associated with
multidrug-resistant tuberculosis (MDR-TB) patient survival in Central China. Between …

SETTING: A referral centre in South Korea. OBJECTIVE: To investigate trends in drug
resistance, treatment modalities and outcomes, and adverse events of multidrug-resistant …

Recent data conflict on the clinical efficacy of later-generation fluoroquinolones, such as
moxifloxacin or levofloxacin, for the treatment of multidrug-resistant tuberculosis (MDR-TB) …

Objective WFQ-228 is a novel developed fluoroquinolone (FQ) displaying potent
antimicrobial activity against various clinical isolates of pathogens, including FQ-resistant …

Background/Purpose Little remains known regarding whether newer FQ with less anti-
mycobacterial activity (gemifloxacin) would reduce treatment delay. Methods We identified …